Kang HJ - Search Results

1

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).

Kim KH, Lee JH, Lee M, Kim HG, Do YR, Park Y, Oh SY, Shin HJ, Kim WS, Park SK, Kong JH, Park MR, Yang DH, Kwak JY, Kang HJ, Mun YC, Won JH. Kim KH, et al. Among authors: kang hj. Cancer Res Treat. 2023 Jan;55(1):304-313. doi: 10.4143/crt.2022.004. Epub 2022 Mar 30. Cancer Res Treat. 2023. PMID: 35381164 Free PMC article. Clinical Trial.

2

Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.

Park YH, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH. Park YH, et al. Among authors: kang hj. Ann Hematol. 2006 May;85(5):285-90. doi: 10.1007/s00277-005-0050-8. Epub 2006 Mar 4. Ann Hematol. 2006. PMID: 16518604

3

Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome.

Park YH, Kim WS, Bang SM, Lee SI, Kang HJ, Na II, Yang SH, Lee SS, Uhm JE, Kwon JM, Kim K, Jung CW, Park K, Ko YH, Ryoo BY. Park YH, et al. Among authors: kang hj. Leuk Res. 2006 Oct;30(10):1253-8. doi: 10.1016/j.leukres.2006.01.018. Epub 2006 Mar 9. Leuk Res. 2006. PMID: 16529813

4

High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: a clinicopathologic study of 18 cases in the Korean population.

Cho JH, Park YH, Kim WS, Oh SY, Cho SI, Kang HJ, Na II, Ryoo BY, Yang SH, Kim K, Jung CW, Park K, Ko YH, Lee SS. Cho JH, et al. Among authors: kang hj. Leuk Lymphoma. 2006 Oct;47(10):2128-31. doi: 10.1080/10428190600783395. Leuk Lymphoma. 2006. PMID: 17071486

5

Consideration of aggressive therapeutic strategies for primary testicular lymphoma.

Park BB, Kim JG, Sohn SK, Kang HJ, Lee SS, Eom HS, Kwon HC, Oh SY, Kang JH, Oh SJ, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS. Park BB, et al. Among authors: kang jh, kang hj. Am J Hematol. 2007 Sep;82(9):840-5. doi: 10.1002/ajh.20973. Am J Hematol. 2007. PMID: 17563078 Free article.

6

Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.

Oh SY, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ. Oh SY, et al. Among authors: kang hj. Eur J Haematol. 2007 Oct;79(4):287-91. doi: 10.1111/j.1600-0609.2007.00925.x. Epub 2007 Aug 10. Eur J Haematol. 2007. PMID: 17692101

7

Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.

Kang HJ, Kim WS, Suh C, Park YH, Kim BS, Yuh YJ, Ryoo BY. Kang HJ, et al. Cancer Chemother Pharmacol. 2008 Jul;62(2):299-304. doi: 10.1007/s00280-007-0607-4. Epub 2007 Oct 9. Cancer Chemother Pharmacol. 2008. PMID: 17922274 Clinical Trial.

8

Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma.

Park BB, Kim JS, Lee YY, Kang HJ, Ryoo BY, Kang JH, Kim HY, Kim BS, Oh SY, Kwon HC, Won JH, Kim K, Park K, Suh C, Kim WS. Park BB, et al. Among authors: kang jh, kang hj. Leuk Lymphoma. 2008 Jan;49(1):88-94. doi: 10.1080/10428190701732861. Leuk Lymphoma. 2008. PMID: 18203017

9

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.

Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, Kim WS, Suh C. Sym SJ, et al. Among authors: kang hj. Cancer Chemother Pharmacol. 2009 Jun;64(1):27-33. doi: 10.1007/s00280-008-0847-y. Epub 2008 Oct 7. Cancer Chemother Pharmacol. 2009. PMID: 18839172 Clinical Trial.

10

Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.

Oh SY, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C. Oh SY, et al. Among authors: kang hj. Invest New Drugs. 2010 Apr;28(2):171-7. doi: 10.1007/s10637-009-9260-6. Epub 2009 May 7. Invest New Drugs. 2010. PMID: 19421710 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,510 results

Search Page